Ionis Pharmaceuticals Inc
XBER:ISI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Ionis Pharmaceuticals Inc
XBER:ISI
|
US |
|
Astrindo Nusantara Infrastruktur Tbk PT
IDX:BIPI
|
ID |
|
L
|
Loblaw Companies Ltd
F:L8G
|
CA |
|
Cordel Group PLC
F:3EW
|
UK |
|
Papa John's International Inc
NASDAQ:PZZA
|
US |
|
C
|
Cohu Inc
F:CU3
|
US |
|
S
|
Sanofi SA
XMUN:SNW
|
FR |
|
Grupo Aeroportuario del Sureste SAB de CV
OTC:ASRMF
|
MX |
|
A
|
Arctic Paper SA
XBER:A0P
|
PL |
|
I
|
Illumina Inc
XMUN:ILU
|
US |
|
A
|
Aedifica NV
SWB:AOO
|
BE |
|
F
|
Franklin Resources Inc
BMV:BEN
|
US |
|
S
|
Steel Dynamics Inc
XMUN:SD5
|
US |
|
E
|
Equity LifeStyle Properties Inc
NYSE:ELS
|
US |
|
Triputra Agro Persada Tbk PT
IDX:TAPG
|
ID |
Wall St Price Targets
ISI Price Targets Summary
Ionis Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ISI is 86.03 EUR with a low forecast of 38.26 EUR and a high forecast of 112.4 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ISI's stock price target?
Price Target
86.03
EUR
According to Wall Street analysts, the average 1-year price target for ISI is 86.03 EUR with a low forecast of 38.26 EUR and a high forecast of 112.4 EUR.
What is the Revenue forecast for Ionis Pharmaceuticals Inc?
Projected CAGR
26%
Over the last 13 years, the compound annual growth rate for Revenue has been 19%. The projected CAGR for the next 8 years is 26%.
What is the Gross Profit forecast for Ionis Pharmaceuticals Inc?
Projected CAGR
24%
The compound annual growth rate for Gross Profit over the next 8 years is 24%.
